Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations
Status:
Terminated
Trial end date:
2017-03-03
Target enrollment:
Participant gender:
Summary
This study will enroll 30 adolescents with bipolar disorder (BD) who are suffering from
symptoms of depression despite already taking a traditional mood-stabilizing medication.
Curcumin will be added to their current medications for 8 weeks. During these 8 weeks, their
mood symptoms will be assessed regularly. Height, weight, and blood pressure will also be
measured repeatedly. Blood tests will be completed before treatment, after 4 weeks of
treatment, and at the end of the study. Blood tests will allow us to determine whether
changes in inflammation and oxidative stress explain curcumin's effect on mood. Finally, we
will use sophisticated technology to measure blood vessel functioning. We have three main
predictions: 1. Curcumin will improve mood symptoms without causing physical problems; 2.
Curcumin will reduce inflammation and oxidative stress, and these reductions will be linked
to improvements in mood; 3. Curcumin will improve blood vessel functioning, and these
improvements will be linked to improved inflammation and oxidative stress.
Phase:
Phase 2
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborator:
The Depressive and Bipolar Disorder Alternative Treatment Foundation